Here’s Why BioTechne (TECH) Traded Lower in Q3

Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here. As we move into 2025, the market’s concentration persists, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned 6.47% in the first nine months of 2025. The fund underperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), which were up 11.35% and the Morningstar Moderate Allocation peer group, which rose 10.73%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $9.478 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was 0.13%, and its shares lost 20.67% of their value over the last 52 weeks. On December 10, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $60.83 per share.

Mairs & Power Balanced Fund stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its third quarter 2025 investor letter:

“The Fund’s overweight to Health Care, combined with its exposure to specific names in the sector, negatively impacted relative performance during the first nine months of 2025. Bio-Techne Corporation (NASDAQ:TECH), which makes high quality ingredients for biopharmaceutical research and production, underperformed due to uncertainty around the funding environment for biopharmaceuticals and biotech research given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne holdings.”

Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 43 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the third quarter, which was 37 in the previous quarter. In the fiscal first quarter of 2026, Bio-Techne Corporation (NASDAQ:TECH) generated $286.6 million, in revenues, down 1% year-over-year both on organic basis and reported basis.  While we acknowledge the risk and potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Bio-Techne Corporation (NASDAQ:TECH) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared ClearBridge Mid Cap Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.